AI assistant
Biocon Ltd. Regulatory Filings 2018
61176_rns_2018-11-12_013b75e7-f047-4045-8063-af2de39b48ba.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Biocon limited
20th KM Hosur Road Electronics City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA 1978PLC003417
Date of submission: November 12, 2018
| To | To |
|---|---|
| The Secretary | The Secretary |
| BSE Limited | National Stock Exchange of India Limited |
| Department of Corporate Services | Exchange Plaza, ~andra Kurla Complex |
| Phiroze Jeejeebhoy Towers, | Mumbai-400 050 |
| Dalal Street, Mumbai-400 001 | Scrip Code- BIOCON |
| Scrip Code - 532523 |
Dear Sir/Madam,
- Sub: Biocon's Generic Formulations Facility in Bengaluru completes U.S. FDA Inspection with No 483 observations
- Ref: Regulations 30 of SEBI Listing Obligations and Disclosure Requirements {LODR) Regulations, 2015.
Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, please find below the "Company Statement" on the subject matter.
"This is to inform you that the U.S. FDA conducted a pre approval inspection of our new Oral Solid Dosage Forms manufacturing facility at Biocon Park/ Bengaluru/ from Nov 05- Nov 09/ 2018. The audit concluded without any observations and no Form 483 was issued. The successful audit of this site reflects our strong commitment to quality and cGMP compliance. N -Company Spokesperson.
We request you to kindly take this to your records as per the requirement of LODR and oblige.
Thanking You, Yours faithfully For Biocon Limited
&ik-~ K~vt ~£
Satish Kumar S S Company Secretary